Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
100%(3 trials)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(3)

Detailed Status

Completed3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

not_yet_recruiting125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

NCT07553338
completedphase_2

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

NCT04347239
completedphase_2

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

NCT04678830
completedphase_2

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

NCT04343651

Clinical Trials (4)

Showing 4 of 4 trials
NCT07553338Phase 2

Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease

Not Yet Recruiting
NCT04347239Phase 2

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Completed
NCT04678830Phase 2

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Completed
NCT04343651Phase 2

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4